UMB-136

• Description :

  UMB-136 is a bromodomain inhibitor. UMB-136 is a promising latency-reversing agent (LRA) for HIV-1 eradication. UMB-136 reactivates HIV-1 in multiple cell models. UMB-136 enhances HIV-1 transcription and increases viral production through the release of P-TEFb[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  Epigenetic Reader Domain; HIV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Epigenetics

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/umb-136.html

• Solubility :

  10 mM in DMSO

• Smiles :

  COC1=CC(C2=C(ON=C2C)C)=CC=C1C3=C(N4C(C=NC=C4)=N3)NC5CCCCC5

• Molecular Formula :

  C24H27N5O2

• Molecular Weight :

  417.50

• Precautions :

  P264-P270-P330-P501

• References & Citations :

  [1]Huang H, et al. A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. Front Microbiol. 2017 Jun 7;8:1035.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2109805-83-4]